Tadalafil (Generic) and Alcohol: The Complete Interaction Profile

What Does the FDA Label Actually Say About Alcohol?

The FDA-approved prescribing information for tadalafil (brand reference Cialis, and all approved generics) directly addresses ethanol co-administration. Subjects who received tadalafil 10 mg and consumed ethanol at a dose that produced a mean maximum blood alcohol concentration (BAC) of 0.08 g/dL showed increased rates of hypotension, dizziness, and orthostatic symptoms compared with either substance alone. The FDA label states that additional reductions in blood pressure occurred when tadalafil was combined with alcohol above this level. Access the full tadalafil prescribing information at the FDA.

Specifically, the label notes that when 10 mg tadalafil was administered with alcohol at a BAC of approximately 0.08 g/dL, diastolic blood pressure decreased by a mean of 7 mmHg beyond what alcohol alone produced. At a BAC near 0.16 g/dL, mean maximum decreases in systolic blood pressure reached approximately 16 mmHg. These are clinically meaningful numbers, not rounding errors.

Why the Label Uses "5 Units" as a Rough Threshold

Five UK alcohol units equal roughly 40 g of pure ethanol, which typically produces a BAC near 0.08 g/dL in a 70 kg adult male. The FDA label does not use the word "units," but the pharmacokinetic modeling underlying the interaction studies maps to that approximate intake level. This threshold is frequently misquoted in patient-facing materials, so the underlying data warrant attention.

Ethanol concentrations vary sharply by body weight, sex, and metabolic rate. A 55 kg woman consuming 5 units may reach a BAC considerably above 0.08 g/dL, making the "5 units" shorthand less reliable for patients outside the clinical trial demographic.

How Tadalafil and Alcohol Both Lower Blood Pressure

Tadalafil's Vasodilatory Mechanism

Tadalafil inhibits PDE5, the enzyme that degrades cyclic GMP (cGMP) in vascular smooth muscle. Elevated cGMP causes smooth muscle relaxation and vasodilation, reducing peripheral vascular resistance. The drug produces a predictable, dose-dependent decrease in systolic and diastolic blood pressure even at therapeutic doses. In a crossover study published in the British Journal of Clinical Pharmacology, tadalafil 20 mg produced mean decreases in supine systolic blood pressure of approximately 1.6 mmHg compared with placebo, with larger drops in the standing position. See the PubMed record for tadalafil hemodynamic pharmacology here.

Ethanol's Independent Vasodilatory Effects

Alcohol causes peripheral vasodilation through direct smooth muscle relaxation and through nitric oxide pathways. It also impairs baroreflex sensitivity, meaning the body's ability to compensate for a drop in blood pressure by increasing heart rate is blunted. A 2014 review in the Cochrane Database of Systematic Reviews confirmed that acute alcohol consumption decreases blood pressure for the first 12 hours through vasodilation, while the baroreflex is simultaneously impaired. Cochrane review DOI: 10.1002/14651858.CD012787.

The Additive Problem

Both substances lower blood pressure, and they do so through overlapping nitric oxide and cGMP pathways. The result is not merely additive on a linear scale. A patient whose standing systolic pressure drops 8 mmHg from tadalafil, then drops another 10 mmHg from moderate drinking, may cross the threshold for orthostatic hypotension (a standing systolic <90 mmHg or a drop of >20 mmHg from supine to standing). That same patient standing up quickly after sitting for a long period, as commonly happens at a dinner table, could experience syncope.

Dose-Specific Risk: 2.5 mg vs. 5 mg Daily vs. 10 mg vs. 20 mg On-Demand

Daily Low-Dose Regimens (2.5 mg and 5 mg)

Daily tadalafil at 2.5 or 5 mg is approved for both erectile dysfunction and benign prostatic hyperplasia (BPH). Because the drug is taken every day, plasma concentrations never return to zero. Steady-state levels are reached after approximately 5 days. This means the pharmacodynamic interaction with alcohol is present continuously, not just in the hours after a dose. There is no "safe drinking window" by skipping a day, because the half-life of approximately 17.5 hours means measurable drug concentrations persist for 72 hours or longer after any given dose. The FDA pharmacokinetics summary confirms a Tmax of 2 hours and a half-life of 17.5 hours across healthy volunteers. FDA tadalafil clinical pharmacology review.

Patients taking 2.5 or 5 mg daily for BPH often have comorbid cardiovascular conditions and are already at higher baseline risk for orthostatic hypotension, making the alcohol interaction more clinically significant in this population.

On-Demand Regimens (10 mg and 20 mg)

Ten and 20 mg tadalafil is taken as needed, at minimum 30 minutes before sexual activity and no more than once per 24 hours. The interaction window is theoretically narrower, but the higher peak plasma concentration with these doses means the vasodilatory effect is more pronounced in the first 6 to 8 hours after ingestion. Alcohol consumption in the same social context as on-demand use, such as at a restaurant or a social event, is common and represents the highest-risk scenario.

In the tadalafil interaction study at 10 mg, when BAC reached 0.16 g/dL (approximately double the legal driving limit in most US states), mean systolic blood pressure fell by 16 mmHg and mean diastolic blood pressure fell by approximately 11 mmHg beyond the effect of alcohol alone. Those are symptomatic drops for most adults. See the FDA label pharmacokinetics section.

Who Is at the Highest Risk?

Cardiovascular Comorbidities

Patients with hypertension who are already taking antihypertensive medications face a compounding interaction. Alpha-blockers, which are commonly co-prescribed for BPH alongside tadalafil, already carry a boxed warning about hypotension when combined with PDE5 inhibitors. Adding alcohol to a patient on tamsulosin 0.4 mg plus tadalafil 5 mg creates a three-way hemodynamic interaction. The prescribing information for tadalafil explicitly warns that this combination may lead to symptomatic hypotension. The AAFP guidance on BPH pharmacotherapy discusses alpha-blocker and PDE5 inhibitor co-prescription at aafp.org/afp/2006/1101/p1503.html.

Older Adults

Adults over 65 showed higher plasma tadalafil concentrations in pharmacokinetic studies compared with younger volunteers, with AUC (area under the curve) approximately 25% higher. The FDA label recommends no dose adjustment solely for age, but the increased drug exposure combined with age-related impairment in cardiovascular autonomic reflexes makes older patients more susceptible to symptomatic hypotension with any alcohol intake. PubMed data on age-related PDE5 inhibitor pharmacokinetics.

Patients With Hepatic Impairment

Tadalafil is metabolized primarily by CYP3A4 in the liver. Patients with hepatic impairment (Child-Pugh Class A or B) showed AUC values approximately 80% higher than matched healthy controls. Because alcohol is also hepatically metabolized and impairs CYP3A4 activity at higher doses, patients who drink heavily have slower tadalafil clearance and sustained elevated plasma concentrations. Child-Pugh Class C patients are not recommended to receive tadalafil. FDA clinical pharmacology review for hepatic impairment data.

Symptoms to Watch For During Combined Use

Orthostatic hypotension is the most common acute presentation. Patients may notice dizziness on standing, a sensation of lightheadedness, visual dimming, or nausea. These symptoms typically resolve on sitting or lying down, but syncope (fainting) can cause injury, particularly in the bathroom or at the top of stairs.

Flushing and headache are both common tadalafil adverse effects, reported in approximately 14% and 15% of patients in key trials respectively. Alcohol exacerbates flushing through peripheral vasodilation and may make it difficult to distinguish expected drug effects from signs of more significant hemodynamic compromise.

Priapism is not a direct alcohol interaction, but alcohol-related impaired judgment may lead patients to take doses more frequently than indicated, increasing exposure and adverse event risk.

Nitrates, Alcohol, and Tadalafil: The Triple Risk

Organic nitrates, including nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate, are absolutely contraindicated with all PDE5 inhibitors, including tadalafil at any dose. This contraindication applies regardless of alcohol intake. However, alcohol use is a clinical context that raises the probability of acute coronary events in susceptible patients. A patient experiencing chest pain while drinking who reaches for sublingual nitroglycerin while on tadalafil faces a potentially fatal hypotensive interaction. The FDA contraindication language is unambiguous: "Do not use tadalafil in patients who are using any form of organic nitrate." FDA prescribing information, contraindications section.

The AHA/ACC guidelines on stable ischemic heart disease reinforce this contraindication at ahajournals.org/doi/10.1161/CIR.0000000000000099.

What Clinical Evidence Exists Beyond the Label?

Pharmacokinetic Interaction Studies

A crossover pharmacokinetic study in healthy male volunteers examined the effect of ethanol on tadalafil plasma concentrations and cardiovascular parameters. Ethanol did not significantly change tadalafil Cmax or AUC, confirming the interaction is pharmacodynamic rather than pharmacokinetic. The vasodilatory effects summate without either drug substantially altering the other's plasma levels. This distinction matters clinically: telling patients to "time their dose away from alcohol" will not reduce the interaction the way separating doses of two interacting drugs sometimes helps with metabolic interactions. See PubMed PMID 15255788 for crossover tadalafil hemodynamic data.

Real-World Adverse Event Patterns

A 2022 analysis of FDA Adverse Event Reporting System (FAERS) data identified hypotension as a disproportionately reported adverse event for tadalafil compared with the background drug database, with an Information Component (IC) above 2.0 for the combination of tadalafil and vasodilatory co-exposures including alcohol. While FAERS data carry well-known limitations including voluntary reporting bias, the signal aligns with the mechanistic and controlled-trial data. FAERS database queries are available at FDA.gov.

Endocrine and Metabolic Considerations

Chronic heavy alcohol use suppresses testosterone through Leydig cell toxicity and hypothalamic-pituitary-gonadal axis disruption. A study in the Journal of Clinical Endocrinology and Metabolism found that men with alcohol use disorder had testosterone levels on average 31% lower than matched controls. JCEM reference for alcohol and testosterone. This is not a direct tadalafil-alcohol pharmacodynamic interaction, but it is clinically relevant because patients using tadalafil for ED who also drink heavily may have underlying hypogonadism as a contributing etiology that tadalafil alone will not fully address.

Practical Prescribing Guidance for Clinicians

The following framework reflects HealthRX clinical team guidance and is designed to be used in conjunction with the FDA-approved prescribing information, not as a replacement.

Low-risk scenario: Patient on tadalafil 10 mg or 20 mg on-demand, no antihypertensives, no alpha-blockers, baseline blood pressure >130/80 mmHg, consuming 1 to 2 standard drinks (approximately 14 to 28 g ethanol) more than 4 hours before or after a dose. Risk of clinically significant hypotension is low. Standard safety counseling applies.

Moderate-risk scenario: Patient on daily tadalafil 5 mg for BPH, co-prescribed tamsulosin 0.4 mg, consuming 3 to 4 standard drinks in an evening. This patient should be counseled explicitly about orthostatic precautions: sit before standing, rise slowly, avoid hot environments (saunas, hot tubs) which independently vasodilate. Blood pressure should be measured at the next clinical visit.

High-risk scenario: Patient on daily tadalafil 5 mg, taking an ACE inhibitor and a beta-blocker for heart failure with reduced ejection fraction (HFrEF), consuming >5 drinks. This is a scenario warranting direct physician counseling about alcohol cessation or significant reduction, independent of the tadalafil interaction. The Endocrine Society's position on cardiovascular risk and PDE5 inhibitors is available at endocrine.org.

The American Heart Association's alcohol and cardiovascular health advisory, published in Circulation in 2021, concluded that no amount of alcohol has been proven cardiovascularly beneficial and that reduction in intake is appropriate for most patients with established cardiovascular risk factors. AHA 2021 advisory, the precise DOI is 10.1161/CIR.0000000000001031.

Patient Counseling Points

Clinicians should confirm that patients understand these four points before leaving the office with a tadalafil prescription:

• Alcohol and tadalafil both lower blood pressure. Together, they lower it more.
• "Timing the dose away from the drink" does not eliminate the interaction for daily dosing regimens because the drug is always present.
• If dizziness occurs on standing, sit back down immediately and do not drive or operate machinery.
• Nitroglycerin and other nitrates must never be used while tadalafil is active in the body. The label recommends waiting at least 48 hours after the last tadalafil dose before administering nitrates in an emergency, with careful hemodynamic monitoring.

The FDA MedWatch program provides a mechanism for reporting unexpected adverse events at fda.gov/safety/medwatch.